Ivosidenib

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.

CHICAGO — In a video interview, Healio spoke with David Andrew Sallman, MD, myeloid section head at Moffitt Cancer Center, about using targeted therapy in patients with myelodysplastic syndrome at ASCO Annual Meeting.

The FDA approved ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.

The FDA granted priority review to ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.

Ivosidenib or enasidenib in combination with chemotherapy showed promising safety and efficacy profiles for newly diagnosed IDH-mutated acute myeloid leukemia, according to a phase 1 trial presented at ASH Annual Meeting and Exposition.

The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

In this video, Healio spoke with Farhad Ravandi, MD, about the promise of maintenance therapy in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.

In this video, Farhad Ravandi, MD, reviews recent advances in acute myeloid leukemia therapies discussed at the Society of Hematologic Oncology Annual Meeting.

The FDA approved ivosidenib tablets for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma.

The addition of ivosidenib tablets to azacitidine prolonged EFS among patients with previously untreated IDH1-mutated acute myeloid leukemia, according to topline data released by the agent’s manufacturer.